MFDS Approves Utilex Immuno-Oncology Drug Phase 1 and 2 Clinical Trial Plans
[Asia Economy Reporter Ji Yeon-jin] Eutilex announced on the 17th that it has received approval from the Ministry of Food and Drug Safety for the Phase 1 and 2 clinical trial plans of the immuno-oncology drug EU101.
The Phase 1 trial will evaluate the safety, efficacy, and pharmacokinetics of EU101, an anti-CD137 (4-1BB) agonist monoclonal antibody, in patients with advanced solid tumors, and will determine the maximum tolerated dose and the recommended dose for Phase 2. The Phase 2 trial will assess the antitumor effects of EU101 in colorectal and non-small cell lung cancers.
Hot Picks Today
!["They Keep Selling Off... Will I Lose Out Because of the SpaceX IPO?" [Weekend Money]](https://cwcontent.asiae.co.kr/asiaresize/93/2026061317395998483_1781340000.jpg)
"They Keep Selling Off... Will I Lose Out Because of the SpaceX IPO?" [Weekend Money]
- "Is the War Finally Over?" Will KOSPI Head Straight for 10,000?... 'This' Will Decide [Weekend Money]
- "Samsung Electronics and SK hynix Have Only Risen Halfway... Sold Out Through Next Year" [Weekend Money]
- "Bought for 670,000 Won and It's the First Thing I Check After Work"... What Gen Z Is Obsessed With Now [The World Is Z Gold]
- "If You Ate Three Bowls, It Could Be Fatal": Thai Noodle Restaurant Used 'Yellow Powder' Found in Trash
The company stated, "EU101 activates and proliferates killer T cells of the immune system that attack cancer in patients with advanced solid tumors, which is expected to minimize treatment side effects, reduce and control tumor size, extend progression-free survival, prolong overall survival, and improve quality of life."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
![[Breaking] Pakistan PM: "Final US-Iran Agreement Expected Within 24 Hours"](https://cwcontent.asiae.co.kr/asiaresize/307/2026041714245830537_1776403498.png)
